Immunocore Holdings annual return on equity
2021
2022
2023
2024
2025
Immunocore Holdings Return on Equity (ROE) Growth & History (IMCR)
Immunocore Holdings's return on equity was −9.58% for fiscal 2025.
View full Immunocore Holdings company overviewImmunocore Holdings annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −9.58% | +4.43 pp |
| 2024 | 2024-12-31 | −14.00% | +1.62 pp |
| 2023 | 2023-12-31 | −15.62% | +2.73 pp |
| 2022 | 2022-12-31 | −18.35% | +97.57 pp |
| 2021 | 2021-12-31 | −115.92% | — |
Immunocore Holdings quarterly return on equity
Q2.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −0.20% | +2.49 pp |
| Q1 2026 | 2026-03-31 | 3.35% | +1.99 pp |
| Q4 2025 | 2025-12-31 | −7.73% | −1.29 pp |
| Q3 2025 | 2025-09-30 | −0.05% | −2.42 pp |
| Q2 2025 | 2025-06-30 | −2.69% | +0.55 pp |
| Q1 2025 | 2025-03-31 | 1.36% | +8.07 pp |
| Q4 2024 | 2024-12-31 | −6.44% | −0.96 pp |
| Q3 2024 | 2024-09-30 | 2.37% | — |
| Q2 2024 | 2024-06-30 | −3.23% | +1.70 pp |
| Q1 2024 | 2024-03-31 | −6.71% | — |
| Q4 2023 | 2023-12-31 | −5.48% | — |
| Q2 2023 | 2023-06-30 | −4.93% | — |
Immunocore Holdings return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Immunocore Holdings's return on equity increased from −115.92% to −9.58%, a change of +106.34 percentage points. The latest reported quarter, Q2 2026, shows −0.20%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunocore Holdings source filings ↗